Answer: CAR-T cell therapy is a relatively new treatment that uses a type of white bloodcells, called T lymphocytes, that are genetically modified to go after a particular target to fightcancer. This therapy was approved by the Food and Drug Administration to treat two types of blood cancers...
Jean-Jacques P . New treatment options for renal cell cancer: critical evaluation. Eur Urol Suppl 2008 ; 7: 443 –446.Patard JJ. New treatment options for renal cell cancer – critical evaluation. Eur. Urol. Suppl. 2008; 7 :443–446....
New Treatment Options for Metastatic Thyroid Cancer. 来自 NCBI 喜欢 0 阅读量: 15 作者:Rajesh,Kunadharaju,Gaurav,Goyal,Avantika,Rudraraju,Peter,T,Silberstein 摘要: Newer multitargeted kinase inhibitors show prolonged overall and progression-free survival in patients with metastatic differentiated and ...
Kumar, MD, professor of medicine, Mayo Clinic Comprehensive Cancer Center, highlighted new treatment options for patients with multiple myeloma, including chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies. Callander noted how CAR-T cell therapies and bispecific engagers have ...
Medulloblastoma and central nervous system (CNS) primitive neuroectodermal tumor (PNET) are primary pediatric brain tumors that require multidisciplinary t... KC De Braganca,RJ Packer - 《Curr Treat Options Neurol》 被引量: 30发表: 2013年 CNS-aspergillosis: are there new treatment options? Invasive...
The researchers say work on expanding more ways to target RAS is still in its early stages but they believe their discovery could lead to new treatments, putting Leeds at the forefront of the fight againstcancer. (2021).
Historically, there are many hard-to-treat mutations of non-small cell lung cancer. Whitney E. Lewis, PharmD, BCOP,a clinical pharmacy specialist at the University of Texas MD Anderson Cancer Center, Houston, Texas, discusses novel therapeutics for patients with non-small...
(TCR) of the cytotoxic T cell. However, thanks to progress in the cancer field, there are methods available that allow to efficiently engage T cells for selective tumor cell killing without the need for a cognate TCR-peptide MHCI interaction. One such an approach is the administration of ...
Dec. 11, 2002 — Two presentations at the 25th Annual San Antonio Breast Cancer Symposium on Dec. 11 suggest new treatment options in advanced breast cancer refractory to conventional chemotherapy. A double-blind crossover trial showed that anastrozole (ARI) should be given as first-line adjuvant...
HONG KONG, April 17 (Xinhua) -- The Faculty of Medicine of the University of Hong Kong (HKUMed) announced on Wednesday that it has pioneered a new stem cell model to help personalize treatment for patients suffering from rare forms of immunodeficiency. ...